SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jargonweary who wrote (62827)9/26/2024 8:09:26 AM
From: weatherproof9 Recommendations

Recommended By
chandler27
diaperdaddy
erippetoe
ghettogoulash
idahoranch1

and 4 more members

  Read Replies (1) of 63325
 
jargon - I recall, pre-Trodelvy approval, passing Daiichi Sankyo's Basking Ridge, NJ location on the way to one of our favorite dinner spots, and sweating each time as we passed it. I never did get a response from Chau as to why IMMU's patents for anti-TROP2 didn't prevent Daiichi from proceeding with that approach. In any event, Trodelvy won out. Reading the article, I'm reminded of how important was the linker and choice of drug conjugate employed in IMMU's approach, which distinguished it from Daiicho's ADC.

Good times; scary times; rewarding times. Now I have to invent new things to sweat about.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News